LL-37 Antimicrobial Peptide: Evidence and Double-Edged Biology

LL-37 is the only antimicrobial peptide of the cathelicidin family produced by the human body — a 37-amino-acid fragment cleaved from a precursor protein called hCAP18 and deployed at infection sites, wounds, and inflamed tissues as a first-line innate defense ^[1]. It kills bacteria by punching holes in their membranes, recruits immune cells, promotes blood-vessel growth, and accelerates wound repair ^[2][3]. You will find it marketed in the peptide space as a treatment for chronic infections, biofilms, non-healing wounds, and immune support. The underlying biology is genuinely compelling and extensively documented. What is far less clear — and what marketing rarely acknowledges — is that injecting LL-37 as a human therapeutic has never been tested in a randomized controlled trial, that endogenous LL-37 is a well-documented driver of pathological inflammation in rosacea and psoriasis, and that its roles in cancer biology are context-dependent and sometimes tumor-promoting. This article reviews what the evidence actually shows — across the extensively studied endogenous biology and the largely unstudied therapeutic application question — drawing a clear and honest line between the two.

What is LL-37? The only human cathelicidin

Humans produce only one member of the cathelicidin family of antimicrobial peptides: hCAP18 (human cationic antimicrobial protein, 18 kDa), encoded by the CAMP gene on chromosome 3. The functional antimicrobial peptide is not hCAP18 itself but its C-terminal cleavage product, LL-37 — named because it starts with two leucine residues (LL) and spans 37 amino acids ^[1]. Neutrophils, epithelial cells, keratinocytes, and macrophages are the primary producers. Upon activation, serine proteases in secretions or at the cell surface (notably kallikrein-5, KLK5, in skin) cleave the hCAP18 precursor and release the active LL-37 peptide ^[2].

This single-cathelicidin limitation is critical context when evaluating preclinical LL-37 research. Mice have four cathelicidin genes; cattle have dozens. Preclinical animal studies frequently involve rodent cathelicidins (such as mCRAMP) that are functionally analogous to but structurally distinct from human LL-37. Extrapolating mouse cathelicidin data to human LL-37 biology — and especially to injectable LL-37 therapy in humans — involves compounding assumptions that are rarely stated in supplement marketing ^[1].

How LL-37 kills pathogens: direct membrane disruption

LL-37’s antimicrobial activity rests on physical chemistry. The peptide is positively charged (cationic) at physiological pH and folds into an amphipathic alpha helix with hydrophilic and hydrophobic faces on opposite sides. This allows it to insert into negatively charged bacterial membranes — enriched in phosphatidylglycerol and cardiolipin, unlike mammalian cell membranes — and disrupt their integrity ^[2]. The proposed mechanisms include the “carpet model” (LL-37 saturates the outer membrane surface and creates transient disruptions) and the “toroidal pore model” (peptides insert perpendicular to the membrane and form stable pores lined by both lipid and peptide). The outcome is membrane permeabilization, ion flux, and bacterial death without requiring cell entry ^[2].

In laboratory conditions, LL-37 shows broad-spectrum antibacterial activity against both Gram-positive and Gram-negative organisms, as well as antifungal and antiviral activity in vitro. It also disrupts bacterial biofilms — the sessile, antibiotic-resistant communities that chronic-infection organisms form — which generates interest in chronic wound contexts. However, in vitro minimum inhibitory concentrations (MICs) for LL-37 are typically much higher than tissue concentrations achievable through injection, and no human clinical trial has tested injectable LL-37 for any infectious disease endpoint ^[2].

Immunomodulatory roles: far beyond antimicrobial killing

LL-37 is not simply a natural antibiotic. Its immunomodulatory functions are extensive and in many physiological contexts more significant than its direct antimicrobial effects, particularly at the sub-MIC concentrations found in human tissue during non-acute inflammation ^[3]. These functions include:

• Chemotaxis and immune cell recruitment. LL-37 is a potent chemoattractant for neutrophils, monocytes, mast cells, and T cells, acting primarily via the formyl peptide receptor-like 1 (FPRL1/FPR2) ^[3]. This accelerates the innate immune response to infection but can amplify inflammation in non-infectious contexts.
• Dendritic cell and macrophage modulation. LL-37 influences toll-like receptor (TLR) signaling, both directly and by forming complexes with nucleic acids that activate intracellular pattern-recognition receptors including TLR7, TLR8, and TLR9 ^[3]. This TLR-activation capacity is central to LL-37’s role in both anti-infective immunity and inflammatory disease.
• Angiogenesis. LL-37 activates the VEGFR2/KDR receptor to promote blood vessel formation, contributing to tissue repair in wound contexts ^[3]. This same pro-angiogenic activity is relevant to tumor vascularization — a concern in malignant disease contexts discussed further below.
• Wound repair and re-epithelialization. In human skin wound biopsies, LL-37 is strongly upregulated at the wound edges during normal healing and markedly reduced or absent at the edges of chronic non-healing ulcers, directly implicating endogenous LL-37 in re-epithelialization ^[4]. This is among the best-supported functions of LL-37 in human tissue.
• Context-dependent anti-inflammatory effects. At certain concentrations and in certain cell types, LL-37 suppresses specific pro-inflammatory cytokine production, making its net immunological effect bidirectional and highly context-dependent ^[2].

The double-edged biology: LL-37 as a pathological driver

The most important honest statement about LL-37 — and the one most consistently absent from wellness-peptide marketing — is that excess or dysregulated endogenous LL-37 is a documented mechanistic driver of pathology in several common conditions. These are not theoretical concerns; they are established findings from peer-reviewed studies in human tissue and validated animal models.

Rosacea: LL-37 as an inflammatory culprit

In a landmark 2007 Nature Medicine study, Yamasaki et al. demonstrated that rosacea patients have significantly elevated levels of hCAP18/LL-37 in facial skin, driven by overactive KLK5 serine protease ^[5]. The LL-37 peptide fragments generated in rosacea skin are atypical — processed differently from those in healthy skin — and are sufficient on their own, when introduced into mouse skin, to produce vascular dilation, erythema, and neutrophil infiltration that closely mimics rosacea lesions. Pharmacological inhibition of KLK5 activity or reduction of LL-37 generation reversed the inflammatory phenotype. Rosacea is, in mechanistic terms, partly a disease of LL-37 dysregulation and excess. The therapeutic implication is the opposite of “supplement with LL-37”: effective rosacea treatments work by reducing KLK5 activity and LL-37 generation, not by adding more ^[5].

Psoriasis: LL-37 as a trigger of adaptive immunity against self

In psoriatic skin, LL-37 plays a different but equally pathological role. Because LL-37 is a cationic peptide, it binds to negatively charged self-DNA released from dying skin cells, forming complexes that are taken up by plasmacytoid dendritic cells and activate TLR9 — a receptor that should never encounter self-DNA under normal circumstances ^[6]. This breaks innate tolerance to self-nucleic acids and triggers a cascade of interferon-alpha production, T-cell activation, and the chronic cytokine loop that defines plaque psoriasis. Lande et al. (2015) showed that multiple cationic antimicrobial peptides in psoriatic skin, including LL-37, cooperate synergistically to amplify this pathway ^[6]. LL-37 is both a biomarker and a mechanistic driver of psoriatic inflammation, not a treatment candidate for it — a distinction that is routinely absent from peptide supplement descriptions of LL-37.

Cancer: a context-dependent and sometimes tumor-promoting role

The cancer biology of LL-37 is complex, and honest reporting requires stating clearly that in several cancer types, LL-37 actively promotes tumor growth. Coffelt et al. published two sequential studies on ovarian cancer: the first (2008) showing that ovarian cancers overexpress hCAP-18 and that LL-37 directly increases ovarian cancer cell proliferation and invasion through EGFR and FPRL1 receptor activation ^[7]; the second (2009, in PNAS) demonstrating that LL-37 recruits multipotent mesenchymal stromal cells — a key source of tumor-supporting stroma — to the ovarian tumor microenvironment, further promoting progression in vivo ^[8].

A 2016 review by Piktel et al. synthesized the broader oncology literature on LL-37 and found that its role is cancer-type specific ^[9]: it tends to be tumor-promoting in ovarian, lung, breast, and endometrial cancers — where tumors upregulate its expression to exploit receptor-mediated proliferation signals and LL-37’s pro-angiogenic VEGFR2 activation — while some studies report possible anti-tumor effects in colon cancer and certain hematologic malignancies. There is no simple “LL-37 fights cancer” or “LL-37 causes cancer” statement that is accurate across cancer types; the pro-tumor roles in multiple common cancers are real, documented, and mechanistically explained ^[9].

Evidence status: endogenous biology versus injectable therapy

The most critical conceptual distinction when evaluating LL-37 claims is between two bodies of evidence: the rich literature on what endogenous LL-37 does within the body (extensive, mechanistically deep, and includes human tissue studies) versus the evidence for injecting LL-37 as a prescribed therapeutic (minimal to nonexistent as controlled human trials go). This distinction is foundational but almost entirely absent from wellness-peptide marketing. Similar evidence gaps apply to other research-stage immune-adjacent peptides: thymosin alpha-1 has the most clinical evidence of any comparable peptide (approved in ~35 countries for hepatitis), and even a gut-targeted peptide like KPV has more mechanistic specificity in its target indication than LL-37 does for any proposed injectable use. In each case, endogenous biology does not substitute for controlled therapeutic trial evidence.

A PubMed search for “LL-37 cathelicidin randomized controlled trial human therapy” returns no published RCT testing exogenous LL-37 as a human intervention. The gap between the extensive endogenous biology literature and the clinical trial evidence base is maximal. For comparison, BPC-157 — another compounded peptide with no FDA approval — has at least three small uncontrolled human pilots totaling fewer than 30 subjects; injectable LL-37 has not reached even that modest bar in any published report.

Regulatory status and safety considerations

• FDA status. LL-37 is not FDA-approved for any human therapeutic indication and is not listed in DailyMed as an approved drug product. No New Drug Application or active Investigational New Drug application is on public record for injectable LL-37 in the United States. Its development as a pharmaceutical remains at a preclinical research stage with no approved formulation ^[10]. Any injectable LL-37 prescribed today is a compounded preparation or grey-market research peptide.
• No evidence-based dose or protocol. Without human PK/PD data, there is no evidence-based dose, injection frequency, or route of administration for therapeutic LL-37. Clinic protocols are empirical and entirely unstudied in any published controlled setting.
• Contraindication signal: rosacea and psoriasis. Individuals with rosacea or psoriasis have documented endogenous LL-37 excess or dysregulation as a mechanistic driver of their condition ^[5][6]. Exogenous LL-37 administration in these patients is theoretically contraindicated — this risk has not been formally studied but flows directly from the mechanistic evidence.
• Oncology risk is real in specific cancer types. LL-37 has documented tumor-promoting roles in ovarian, lung, breast, and endometrial malignancies ^[7][8][9]. Any patient with an active or occult malignancy in these cancer types faces an unstudied but mechanistically plausible risk from exogenous LL-37.
• Pro-angiogenic activity. LL-37 activates VEGFR2 and promotes angiogenesis ^[3]. While beneficial for wound repair in healthy tissue, this activity in inflammatory or neoplastic contexts could amplify pathology. The clinical significance of this effect from injectable LL-37 is unstudied.
• Compounding quality risk. No FDA-approved LL-37 product exists. Peptide purity, sterility, dose accuracy, and storage stability are entirely dependent on the compounding pharmacy's quality systems, which are not uniformly inspected or validated by the FDA.
• WADA status. LL-37 has reported antimicrobial and tissue-repair activities; competitive athletes should verify its current classification under the WADA Prohibited List before any use, as antimicrobial peptides and their derivatives are subject to periodic classification review.